Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Entities associated with director Luke Evnin sold Werewolf Therapeutics, Inc. stock over three days under a pre-arranged plan. Investment vehicles including MPM Asset Management LLC, MPM BioVentures 2014 funds, MPM Asset Management Investors BV2014 LLC and MPM Oncology Innovations Fund, L.P. sold a total of 205,911 shares of Common Stock in open-market transactions on April 27, 28 and 29, 2026 at weighted average prices of $0.85, $0.73 and $0.69 per share, respectively.
After these indirect sales, the affiliated entities together held 1,953,949 shares. The filing notes the transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 26, 2026 and that Evnin disclaims beneficial ownership beyond his pecuniary interest.